Capstone Therapeutics (CAPS) Competitors $1.24 -0.05 (-3.88%) As of 08/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock CAPS vs. NMTR, OGEN, PTPI, ZVSA, HSTO, TRVN, SRNE, PBLA, BPTSY, and HEPAShould you be buying Capstone Therapeutics stock or one of its competitors? The main competitors of Capstone Therapeutics include 9 Meters Biopharma (NMTR), Oragenics (OGEN), Petros Pharmaceuticals (PTPI), ZyVersa Therapeutics (ZVSA), Histogen (HSTO), Trevena (TRVN), Sorrento Therapeutics (SRNE), Panbela Therapeutics (PBLA), Biophytis (BPTSY), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "pharmaceutical products" industry. Capstone Therapeutics vs. Its Competitors 9 Meters Biopharma Oragenics Petros Pharmaceuticals ZyVersa Therapeutics Histogen Trevena Sorrento Therapeutics Panbela Therapeutics Biophytis Hepion Pharmaceuticals 9 Meters Biopharma (NASDAQ:NMTR) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends. Do institutionals & insiders have more ownership in NMTR or CAPS? 22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 2.5% of Capstone Therapeutics shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by insiders. Comparatively, 42.8% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, NMTR or CAPS? Capstone Therapeutics has higher revenue and earnings than 9 Meters Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/ACapstone Therapeutics$43.42M0.00-$2.56MN/AN/A Which has more volatility & risk, NMTR or CAPS? 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -0.8, indicating that its share price is 180% less volatile than the S&P 500. Does the media favor NMTR or CAPS? In the previous week, Capstone Therapeutics had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Capstone Therapeutics and 0 mentions for 9 Meters Biopharma. Capstone Therapeutics' average media sentiment score of 0.81 beat 9 Meters Biopharma's score of 0.00 indicating that Capstone Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 9 Meters Biopharma Neutral Capstone Therapeutics Positive Is NMTR or CAPS more profitable? Capstone Therapeutics' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets 9 Meters BiopharmaN/A -584.97% -159.45% Capstone Therapeutics N/A N/A N/A SummaryCapstone Therapeutics beats 9 Meters Biopharma on 7 of the 9 factors compared between the two stocks. Get Capstone Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPS vs. The Competition Export to ExcelMetricCapstone TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$203K$3.10B$5.67B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E RatioN/A20.3830.5825.12Price / Sales0.00354.10460.38114.01Price / CashN/A42.3037.4059.05Price / Book-0.068.659.096.18Net Income-$2.56M-$54.65M$3.25B$264.89M7 Day Performance-6.06%6.58%7.42%4.22%1 Month Performance-16.78%7.54%5.50%2.02%1 Year PerformanceN/A13.73%30.67%24.22% Capstone Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPSCapstone TherapeuticsN/A$1.24-3.9%N/AN/A$203K$43.42M0.0038News CoverageEarnings ReportHigh Trading VolumeNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220Gap UpOGENOragenics0.3594 of 5 stars$1.25-0.8%N/A-97.3%$1.03MN/A-0.185News CoverageShort Interest ↓PTPIPetros Pharmaceuticals0.2349 of 5 stars$0.03+7.3%N/A-99.6%$1.01M$5.11M-0.0120ZVSAZyVersa Therapeutics0.7157 of 5 stars$0.19-6.8%N/A-94.9%$969KN/A0.002News CoverageGap DownHSTOHistogenN/A$0.00flatN/A-99.9%$918K$19K0.0020TRVNTrevena1.1462 of 5 stars$0.91flat$5.00+449.5%-92.6%$873K$443K-0.0240Short Interest ↑SRNESorrento Therapeutics0.846 of 5 stars$0.00flatN/A-79.0%$827K$60.32M0.00800High Trading VolumePBLAPanbela Therapeutics1.1224 of 5 stars$0.17flatN/A-57.3%$825KN/A0.006Negative NewsShort Interest ↓BPTSYBiophytisN/A$1.81flatN/A-67.2%$634KN/A0.0030Short Interest ↓HEPAHepion Pharmaceuticals0.9186 of 5 stars$0.04+2.1%N/A-99.8%$491KN/A-0.0120News CoverageShort Interest ↓ Related Companies and Tools Related Companies NMTR Alternatives OGEN Alternatives PTPI Alternatives ZVSA Alternatives HSTO Alternatives TRVN Alternatives SRNE Alternatives PBLA Alternatives BPTSY Alternatives HEPA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPS) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access